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STRUCTURED ABSTRACT (250 words) 
Background: Few large studies describe initial disease trajectories and subsequent mortality 
in people with head and neck cancer. This is a necessary first step to identify the need for 
palliative care and associated services.  
Aim: To analyse data from the Head and Neck 5000 study to present mortality, place and 
mode of death within 12 months of diagnosis.   
Design: Prospective cohort study. 
Participants: In total, 5402 people with a new diagnosis of head and neck cancer were 
recruited from 76 cancer centres in the United Kingdom between April 2011 and December 
2014.  
Results: Initially, 161/5402 (3%) and 5241/5402 (97%) of participants were treated with  ?non-
curative ? ĂŶĚ  ?ĐƵƌĂƚŝǀĞ ? intent respectively. Within 12 months, 109/161 (68A? ? ŝŶ ƚŚĞ  ?ŶŽŶ-
curative ? group died compared with 482/5241 (9%) in the  ?ĐƵƌĂƚŝǀĞ ? group. Catastrophic bleed 
was the terminal event for 10.4% and 9.8% of people in  ?non-ĐƵƌĂƚŝǀĞ ?ĂŶĚ ?ĐƵƌĂƚŝǀĞ ?groups 
respectively; terminal airway obstruction was recorded for 7.5% and 6.3% of people in the 
same corresponding groups. Similar proportions of people in both groups died in a hospice 
( ? ? ? ?A? ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?; 23.5%  ?ĐƵƌĂƚŝǀĞ ?) and 45.7% of the  ?ĐƵƌĂƚŝǀĞ ?group died in hospital.  
Conclusions: In addition to those with incurable head and neck cancer, there is a small but 
significant  ?ĐƵƌĂƚŝǀĞ ?subgroup of people who may have palliative needs shortly following 
diagnosis. Given the high mortality, risk of acute catastrophic event and frequent hospital 
death, clarifying the level and timing of palliative care services engagement would help 
provide assurance as to whether palliative care needs are being met.  
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KEY STATEMENTS 
What is already known about the topic?  
x People with head and neck cancer have unique and complex needs due to the impact 
from both the disease and its treatment 
x Early engagement of Specialist Palliative Care has been shown to have a beneficial 
impact on cancer patients and family carers but the best way to integrate this care for 
those with head and neck cancer needs further clarification.    
 
What this paper adds?  
x Two-thirds of people with head and neck cancer ƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚĂŶĚ
almost 10% of those treated ǁŝƚŚ ?ĐƵƌĂƚŝǀĞŝŶƚĞŶƚ ?died within the 12 months following 
initial diagnosis. 
x Over a fifth of people with head and neck cancer, irrespective of their original 
treatment intent, died in a hospice which is greater than the proportion of those with 
cancer as a whole. 
x Between 6 - 11% died from acute bleeding or airway obstruction.   
 
Implications for practice, theory or policy 
x Further understanding about current levels and timing of palliative care service 
engagement would be a useful next step in determining to what degree palliative care 
needs for those with head and neck cancer are met.  
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x Identifying ƉĞŽƉůĞǁŝƚŚ ?ŚŝŐŚƌŝƐŬ ?ŚĞĂĚĂŶĚŶĞĐŬĐĂŶĐĞƌĂƚƚŚĞƉŽŝŶƚŽĨĚŝĂŐŶŽƐŝƐ and 
exploring their care needs in greater detail also represents an area of further study.   
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BACKGROUND  
 
Evidence to support the benefits of early access to Specialist Palliative Care, often concurrent 
with active oncology care, has expanded rapidly over the last decade. Studies suggest that 
Specialist Palliative Care improves quality of life, symptom control and aspects of doctor-
patient communication.1-6 There are a number of unanswered questions, however, relating 
to the optimum service model and how to promote timely patient identification and referral.1 
Previous studies have mainly focused on solid organ tumours such as lung and upper 
gastrointestinal cancer. Little attention has been paid to people with head and neck cancer 
despite the well-recognised complexities of the both the cancer and its treatment.7 
FƵŶĚĂŵĞŶƚĂůĐŚĂŶŐĞƐĐĂŶŽĐĐƵƌĂĨĨĞĐƚŝŶŐŝŶĚŝǀŝĚƵĂůƐ ?appearance8, 9 and their ability to eat, 
speak and breathe.10-12 The subsequent psychological and social impact for both those with 
head and neck cancer and their family carers is significant.13  
 
At presentation, about 60% of people with head and neck cancer have advanced disease 
(stage III or IV) and recurrence following treatment is high.14,15 The median overall survival for 
those with recurrent or metastatic disease is less than one year.16 Engagement with Specialist 
Palliative Care services can vary. One American study observed that individuals having a 
diagnosis of head and neck cancer ǁĂƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ĞĂƌůǇ ƌĞĨĞƌƌĂů ƚŽ  ?^ƵƉƉŽƌƚŝǀĞ ĂŶĚ
ƉĂůůŝĂƚŝǀĞĐĂƌĞ ?ƐĞƌǀŝĐĞƐ.17 Another study involving those with terminal head and neck cancer 
(defined as having distal metastatic disease), however, suggested under-utilisation of in-
patient palliative care consultations.18 In order to develop and direct targeted services to best 
support people with head and neck cancer, a greater understanding of the potential palliative 
care needs and challenges for this population is required.19 There are few large-scale studies 
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describing initial disease trajectories and subsequent mortality of people with head and neck 
cancer  W a necessary first step in identifying the potential need for palliative care.  
 
We present results from the  ?Head and Neck 5000 ? resource, 20, 21 a large clinical cohort study 
in people with head and neck cancer within the United Kingdom (UK). We focus on disease 
trajectories; compare mortality for those treated ǁŝƚŚ  ?non-ĐƵƌĂƚŝǀĞ ?and  ?ĐƵƌĂƚŝǀĞ ?intent, 
examine the place and mode of death for those who died within the first 12 months and 
assess the subsequent mortality during the study period.  
 
 
METHODS 
 
Study population 
The study methods have previously been described.20 Within 76 UK cancer centres, all people 
aged 16 years or over, with a new diagnosis of head and neck cancer were eligible. People 
treated with curative intent were recruited before treatment started (unless part of a 
diagnostic procedure) and participants offered palliative support were recruited as soon after 
diagnosis as possible.22      
 
Recruitment 
Participants were recruited between 1st April 2011 and 31st December 2014. Written 
informed consent, obtained by research nurses based in local centres, included consent for 
collection of clinical data from case records and record linkage.   
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Treatment intent 
ĂƐĞůŝŶĞĚĂƚĂĐĂƉƚƵƌĞĨŽƌŵƐĐŽŵƉůĞƚĞĚďǇƚŚĞƌĞƐĞĂƌĐŚƐŝƚĞƐǁĞƌĞƵƐĞĚƚŽĚĞĨŝŶĞ ?ĐĂŶĐĞƌƉůĂŶ
ŝŶƚĞŶƚ ? ?21 defined as the intention of treatment, as specified in the final pre-treatment multi-
ĚŝƐĐŝƉůŝŶĂƌǇ ƚĞĂŵ ?  ?Dd ? ŵĞĞƚŝŶŐ. The research teams at each site were subsequently (4 
months later) asked to indicate which option best reflected the treatment received (rather 
than planned) and were defined as:  
x Curative: underwent treatment that intends, however slight the chance of success, 
to cure.  
x Palliative anti-cancer: underwent treatments such as chemotherapy, radiotherapy or 
surgery but it is known that the cancer cannot be cured.  
x ^ƵƉƉŽƌƚŝǀĞ PƌĞĨĞƌƐƚŽ ?ďĞƐƚƐƵƉƉŽƌƚŝǀĞĐĂƌĞ ?aimed at relieving symptoms but is not as 
ŝŶƚĞŶƐŝǀĞĂƚƌĞĂƚŵĞŶƚĂƐ ?ƉĂůůŝĂƚŝǀĞĂŶƚŝ-ĐĂŶĐĞƌ ? ?ŝƚŝƐŬŶŽǁŶƚŚĂƚƚŚĞĐĂŶĐĞƌĐĂŶŶŽƚ
be cured.   
x No specific anti-cancer: patient declined to have any treatment.  
 
Within this study, participants were categorised into two groups reflecting the treatment they 
received - thosĞƚƌĞĂƚĞĚǁŝƚŚ ?ĐƵƌĂƚŝǀĞ ? ŝŶƚĞŶƚ ĂŶĚƚŚŽƐĞƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞŝŶƚĞŶƚ ? 
(i.e. a combination of the other groups).    
 
Baseline data collection 
 
Health, lifestyle and socio-demographic measurements  
Socio-demographic, health and lifestyle measures including age at consent, gender, smoking 
status, alcohol consumption and World Health Organisation (WHO) performance status were 
collected using self-report questionnaires.20 Smoking status was categorised as never, current 
or former smoker. Alcohol consumption was categorised as non-drinker, moderate drinker 
(ख़14 units per week for men and women), hazardous drinker (14 - 50 units / week for men 
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and 14 - 35 units / week for women) and harmful drinker (>50 units / week for men and >35 
units / week for women), where one unit of alcohol = 8g/10ml ethanol. 23  WHO performance 
status ƌĂŶŐĞĚĨƌŽŵǌĞƌŽ ? ?ŶŽƌŵĂůĂĐƚŝǀŝƚǇ ? ?ƚŽĨŽƵƌ  ? ?ĐŽŶĨŝŶĞĚ to bed or chair more than 50 
percent of the time).24 We linked the English Index of Multiple Deprivation (IMD) 2010 
ƋƵŝŶƚŝůĞƐƵƐŝŶŐƉĂƌƚŝĐŝƉĂŶƚƐ ?ŚŽŵĞƉŽƐƚĐŽĚĞ Wgroup 1 represented the most deprived people; 
group 5 represented the least deprived people.25 
 
Clinical measures  
Anatomical site was recorded using the International Classification of Diseases (ICD) 10 
codes.26 Where possible, clinical data were checked against pathology forms. We grouped 
anatomical site into: lip and oral cavity squamous cell carcinoma (SCC) (C00, C02-C06), 
oropharynx SCC (C01, C05.1, 2, C09.0, 1, 9, C10.0, 2, 3), larynx SCC (C32.0, 1, 2, C10.1), other 
SCC (C07-C08, C11-C14, C30-C31, C41.1, C69.5), and other non-SCC (and ICD code with non-
SCC histology) tumours.  
 
Other clinical data included clinical stage, co-morbidity status, treatment modality and human 
papilloma virus (HPV) status. Stage was grouped into four categories (I, II, III, IV) using the 
Tumour, Node and Metastasis version 7.27 Co-morbidity was measured using the Adult 
Comorbidity Evaluation28 - participants were grouped into four categories including no co-
morbidity, mild co-morbidity, moderate decompensation, severe decompensation. 
Treatment was defined at four months based on the treatment received (rather than 
planned). Anti-cancer treatments were defined as: single modality (subdivided into  ?ƐƵƌŐĞƌǇ
ŽŶůǇ ? ?  ?ƌĂĚŝŽƚŚĞƌĂƉǇ ŽŶůǇ ? Žƌ  ?ĐŚĞŵŽƚŚĞƌĂƉǇ ŽŶůǇ ?); chemoradiotherapy only; surgery 
combined with other anti-cancer treatment; no anti-cancer treatment. HPV status was 
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defined as a serological response to HPV 16 E6 protein using a glutathione S-transferase 
multiplex assay undertaken at the German Cancer Research Center (DKFZ), Heidelberg, 
Germany. A cut-off value of more than 1000 Median Fluorescence Intensity (MFI) units 
defined a positive response.29, 30   
 
Follow-up.  
Follow-up questionnaires were sent out four and 12 months after the participant was 
recruited and research nurses collected updated clinical information from hospital medical 
records concurrently. On 11th October 2018, the cohort was linked to the National Office of 
Statistics mortality data, which provided at least three and a half years of follow-up.  
 
Statistical analysis  
Demographic data are presented along with p-values to test for differences between 
 ?ĐƵƌĂƚŝǀĞ ? ĂŶĚ  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?groups. Survival time was measured as the time from 
study consent until either death or the end of the most recent follow-up period. Cox 
Proportional Hazards models were estimated with 95% confidence intervals (CIs) to 
determine differences in the predictors of all-cause mortality for each variable included 
in the analysis, (both unadjusted and adjusted for age and sex) and to compare 
ďĞƚǁĞĞŶ  ?ĐƵƌĂƚŝǀĞ ?ǀĞƌƐƵƐ  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŵŽĚĞůƐ. P-values were displayed to test for 
the trend across each group for ordinal variables, and individual p-values were 
displayed to test for the differences between hazard ratios (HRs) for unordered 
variables. Descriptive data from mortality forms were presented along with 
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percentages and 95% CI for proportions. All statistical analyses were performed using 
Stata (Version 15.0).31 
Ethical approval  
The study was approved by the National Research Ethics Committee (South West Frenchay 
Ethics Committee, reference 10/H0107/57, 5th November 2010) and approved by the 
research and development departments for participating NHS Trusts. 
 
RESULTS  
 
Study population 
From the 5511 participants who consented, 109 were excluded from analyses (Figure 1). From 
the remaining 5402, 161 (3%) were ƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚ and 5241 (97%) treated 
ǁŝƚŚ ?ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚ ?Comparison of baseline data between those treated with  ?ŶŽŶ-curative ? 
and  ?curative ? intent showed ƚŚŽƐĞǁŝƚŚŝŶƚŚĞ ?ŶŽŶ-cƵƌĂƚŝǀĞ ?ŐƌŽƵƉwere older, had a higher 
proportion of moderate or severe co-morbidities, poorer WHO performance status and were 
ƚǁŝĐĞĂƐůŝŬĞůǇƚŽƉƌĞƐĞŶƚǁŝƚŚ^ƚĂŐĞ/sĚŝƐĞĂƐĞ ?dĂďůĞ ? ? ?ĚĚŝƚŝŽŶĂůůǇ ?ƚŚŽƐĞǁŝƚŚŝŶƚŚĞ ?ŶŽŶ-
ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉǁĞƌĞŵŽƌĞůŝŬĞůǇ ƚŽŚĂǀĞ ?ŽƚŚĞƌ^ ?ĂƐƚŚĞŝƌƉƌŝŵĂƌǇƚƵŵŽƵƌƐŝƚĞ ?ďĞ,Ws-
negative, not undergo surgery but rather have single or no definitive anti-cancer treatment.  
 
Mortality up to 12 months following diagnosis 
Within the first four months, 39/161 (24%) of those treated with  ?non-curative ? intent had 
died compared with 123/5241 (2.3%) of those in the  ?curative ? group. At 12 months, 109/161 
 ? ? ? ? ?A? ?ŽĨƚŚŽƐĞŝŶƚŚĞ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉŚĂĚĚŝĞĚ ?&ƌŽŵƚŚĞŝŶŝƚŝĂů ?ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚŐƌŽƵƉ ?
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482/5241 (9%) had died and 162/5241 (3%) were now ďĞŝŶŐ ƚƌĞĂƚĞĚ ǁŝƚŚ  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?
intent (Figure 1). In total, 591/5402 (10.9%) had died within the initial 12 months following 
diagnosis.       
 
Overall survival results   
Participants were followed up for at least three and a half years. During this time, most people 
treated at baseline with  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚĚŝĞĚ ?ŶA? ? ?7/161, 91.3%) as did 30% of those 
treated curatively (n=1573/5241).  
 
WĞŽƉůĞ ŝŶ ƚŚĞ  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ? ŐƌŽup had markedly worse survival than those with stage IV 
ƚƵŵŽƵƌƐ ŝŶ ƚŚĞ  ?ĐƵƌĂƚŝǀĞ ? ŐƌŽƵƉ  ?&ŝŐƵƌĞ  ? ? ? tŝƚŚŝŶƚŚĞ  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ? ŐƌŽƵƉ ? ƚŚŽƐĞ ǁŝƚŚ Ă
poorer WHO performance status were more likely to die within the total study period (Table 
2). tŝƚŚŝŶƚŚĞ ?ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉ ?ƚŚŽƐĞǁŚŽǁĞƌĞŽůĚĞƌ ?ŵĂůĞ ?ŚĂĚƐĞǀĞƌĞĐŽ-morbidities, poor 
WHO performance status, a higher deprivation score, were currently smoking and with more 
advanced disease stage, were more likely to die within the study period (Table 3). Those who 
were treated solely with chemotherapy had a markedly higher hazard ratio (HR). There were 
ŽŶůǇ ? ?ƉĞŽƉůĞŝŶƚŚŝƐŐƌŽƵƉ ?ŚŽǁĞǀĞƌ ?ĂŶĚŶŝŶĞǁĞƌĞŝĚ ŶƚŝĨŝĞĚĂƐ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ǁŝƚŚŝŶ ? ?
months.  
 
PĞŽƉůĞŝŶƚŚĞ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉŚĂĚĂ nine-fold higher risk of death (unadjusted HR 9.22 
(95% CI 7.8 to 11.0)) ĐŽŵƉĂƌĞĚǁŝƚŚƚŚŽƐĞŝŶƚŚĞ ?ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉ (Supplementary Table 1). 
Following full adjustment, the hazard ratio attenuated but they still had almost a three-fold 
higher risk of all-cause mortality than ƚŚĞƉĂƚŝĞŶƚƐŝŶƚŚĞ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉ ?HR 2.95 (95% 
CI 2.0 to 4.3).  
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Cause, mode and place of death   
Mortality feedback forms were completed for 549/591 (93%) participants who died within 
the first year of the study (Table 4). From those in the  ?non-curative ? group, 5/48 (10.4%) 
people who had died within the first 12 months had a catastrophic bleed and 3/40 (7.5%) had 
an airway obstruction as a terminal event. Similarly, 22/224 (9.8%) and 12/192 (6.3%) from 
those in the  ?curative ? group had a bleed or airway obstruction respectively.  
 
From those who had died within the first 12 months and had a completed mortality form, 
tŚĞƌĞǁĂƐĂƐƵŐŐĞƐƚŝŽŶƚŚĂƚŵŽƌĞŽĨƚŚŽƐĞŝŶƚŚĞ ?curative ? group died in hospital compared 
ǁŝƚŚƚŚĞ ?non-curative ? group (p=0.09) (Table 4). Similar proportionƐŽĨƚŚŽƐĞǁŝƚŚŝŶƚŚĞ ?ŶŽŶ-
ĐƵƌĂƚŝǀĞ ? ? ? ? ? ?A? ?ĂŶĚ ?ĐƵƌĂƚŝǀĞ ? ? ? ? ? ?A? ?ŐƌŽƵƉƐdied in a hospice.  
 
DISCUSSION  
 
Main findings  
The vast majority of people within this cohort were treated with curative intent. The small 
ƉƌŽƉŽƌƚŝŽŶƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚŚĂĚƌĞĐŽŐŶŝƐĞĚƌŝƐŬĨĂĐƚŽƌƐthat were associated 
with poor prognosis including increasing age, advanced stage of disease and multiple co-
morbidities. Two-ƚŚŝƌĚƐŽĨƚŚŽƐĞŝŶŝƚŝĂůůǇƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚĂŶĚĂůŵŽƐƚ ? ?A?ŽĨ
those treated curatively, died within the first 12 months following initial head and neck cancer 
diagnosis.  The latter group potentially represents a cohort of people who after undergoing 
initial curative treatment were quickly identified to have residual or recurrent cancer, 
necessitating a change in treatment intent to a palliative approach.  
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During the study period, tŚĞƌŝƐŬŽĨĚĞĂƚŚǁĂƐŽǀĞƌŶŝŶĞƚŝŵĞƐŐƌĞĂƚĞƌĨŽƌƚŚŽƐĞŝŶƚŚĞ ?ŶŽŶ-
ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉĐŽŵƉĂƌĞĚǁŝƚŚƚŚĞ ?ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉ ?From the participants who died within 
12 months of diagnosis, over one fifth of people with head and neck cancer, irrespective of 
their original treatment intent, died in a hospice. 
 
What this study adds and implications for practice   
When an individual is diagnosed with head and neck cancer, survival and treatments that 
offer the best chance of cure are usually the primary concern. 32 Hence, it is unsurprising that 
ŵŽƐƚ ƉĞŽƉůĞ ŝŶ ŽƵƌ ƐƚƵĚǇ ǁĞƌĞ ƚƌĞĂƚĞĚ ǁŝƚŚ  ?ĐƵƌĂƚŝǀĞ ? ŝŶƚĞŶƚ Ăƚ ƚŚĞ point of diagnosis. 
Knowledge about place of death helps our understanding regarding service needs and 
development. From those who died within the first 12 months, over a fifth of people with 
head and neck cancer, irrespective of their original treatment intent, died in a hospice. This is 
greater than the observed numbers of head and neck cancer ĚĞĂƚŚƐ ŝŶ Ă  ?ŚŽƐƉŝĐĞ ǁĂƌĚ ?
(14.6%) within a large Taiwanese study. 33 The observed proportion of hospice deaths is also 
greater than the 16% of people with all forms of cancer who died within a hospice in England 
between 1993 and 2010.34 In part, this may reflect the complexities of care, including the risk 
of acute catastrophic events and the need for specialist care. Within this cohort, between six 
and 11% had a catastrophic event as a terminal event, greater than the 3-5% previously 
ƌĞƉŽƌƚĞĚƚŽŚĂǀĞ ?ĐĂƌŽƚŝĚďůŽǁŽƵƚƐǇŶĚƌŽŵĞ ?.35  
 
Different models of providing palliative care exist,36 but the optimum model for those with 
head and neck cancer remains unclear. Compared with other cancers, people with head and 
neck cancer have a high prevalence of palliative care needs, 37 complex symptoms, 38 and 
frequently require opioids and other medications to help with symptom control. 39 Hence, 
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developing and testing different models of care should be the focus of future studies. Within 
India, the first randomised controlled study assessing the impact of early Specialist Palliative 
Care with stage IV head and neck cancer patients is currently being conducted (Muckaden 
MA, personal communication). Specialist Palliative Care is a limited resource. Hence, it is 
important to identify patients who most need specialist input and those who may benefit 
from a broader palliative and supportive care approach provided by the wider multi-
disciplinary team. From our study, there appear to be two groups where screening for unmet 
needs and linkage into specialist palliative care services may be required shortly after 
diagnosis: those initially ƚƌĞĂƚĞĚǁŝƚŚ ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ?ŝŶƚĞŶƚand a  ?ŚŝŐŚƌŝƐŬ ?ƐƵďŐƌŽƵƉ of those 
ŝŶŝƚŝĂůůǇ ƚƌĞĂƚĞĚ ǁŝƚŚ  ?ĐƵƌĂƚŝǀĞ ? ŝŶƚent, but who die within the first 12 months. Trying to 
prospectively identify this latter group remains a challenge.  
 
To further understand the patient journeys, especially within the last year of life, undertaking 
research to explore the patient and family carer experience, symptom burden and the level 
of healthcare utilisation would be beneficial. As part of a German multi-centre prospective 
study, the symptoms and needs of head and neck cancer patients at the point of incurability 
are being assessed using self-reported tools.40 An alternative method would be to undertake 
both longitudinal quantitative and qualitative research recruiting people with head and neck 
cancer and their families as they move from curative disease to palliative care. The addition 
ŽĨ ůŽŶŐŝƚƵĚŝŶĂůƋƵĂůŝƚĂƚŝǀĞŵĞƚŚŽĚŽůŽŐǇƉƌŽǀŝĚĞƐƌŝĐŚ ŝŶƐŝŐŚƚƐ ŝŶƚŽĂŶ ŝŶĚŝǀŝĚƵĂů ?ƐĐŚĂŶŐŝŶŐ
experience of their illness. 41-43   
 
Knowing more about the factors influencing treatment decision-making, especially when the 
chance of cure is small, would also be beneficial. Within the UK, a previous study suggested 
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only 25% of head and neck cancer multi-disciplinary meetings (forums used to discuss the 
diagnosis and treatment planning) have direct presence from Specialist Palliative Care 44 and 
it is unclear how much this situation has changed. A Dutch study examined the methods in 
which prognosis was communicated to people with head and neck cancer at various stages 
of their illness. 45 Specific prognostic information was often not included in these discussions 
and subsequent work is being conducted to help enhance shared decision-making. 45  
 
&ŝŶĂůůǇ ?ŵŽƌĞĚĞƚĂŝůĞĚĂŶĂůǇƐŝƐŽĨƐƉĞĐŝĨŝĐƐŝƚƵĂƚŝŽŶƐ ?ƵƐŝŶŐĂ ?ĐŽŶĨŝĚĞŶƚŝĂůĞŶƋƵŝƌǇ ?ĂƉƉƌŽĂĐŚ ?
could help to better understand the circumstances of deaths leading up to an acute 
catastrophic event and identify ways that these could be predicted, prevented or better 
managed.  
 
Strengths and limitations of the study 
This study has several strengths. First, it is a large, prospective, national clinical cohort study 
which recruited people newly diagnosed with head and neck cancer.  Second, those treated 
with  ?ŶŽŶ-ĐƵƌĂƚŝǀĞ ? ĂŶĚ  ?ĐƵƌĂƚŝǀĞ ? ŝŶƚĞŶƚ ǁĞƌĞ ƌĞĐƌƵŝƚĞĚ ĐŽŶƚĞŵƉŽƌĂŶĞŽƵƐůǇ ĂůůŽǁŝŶŐ
comparisons between groups. Finally, the study collected prospective data on mortality and 
place of death.   
 
The study had several weaknesses. First, tŚĞŶƵŵďĞƌƐǁŝƚŚŝŶƚŚĞ ?ŶŽn-ĐƵƌĂƚŝǀĞ ?ŐƌŽƵƉ were 
small. dŚŝƐůŝŵŝƚƐƚŚĞƐƚƵĚǇ ?ƐƉŽǁĞƌĂŶĚŝƐƌĞĨůĞĐƚĞĚďǇƚŚĞwide confidence intervals for some 
analyses.  Second, possible issues including perceived study burden and gatekeeping, may 
have limited numbers of palliative participants who were recruited to the study. Additionally, 
we do not have the reasons for non-participation e.g. lacks capacity, unwilling to complete 
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study questionnaires. It is possible that those treated with palliative intent and subsequently 
recruited are not representative of all people treated with palliative intent.46, 47 In one study, 
84/390 (21.5%) people with head and neck cancer were treated with palliative intent 
following diagnosis.48 Third, the extent of missing data, especially for the place and mode of 
death, and the fact that data were recorded by the research team (rather than the clinical 
team) may limit their accuracy. More robust methods of eliciting this information would be 
useful within future research. Finally, the limited information available about the timing of 
referral and level of palliative care intervention leading up to death meant it was not possible 
to describe care pathways in detail.   
 
CONCLUSION   
In addition to those with incurable head and neck cancer, there is a small but significant 
 ?ĐƵƌĂƚŝǀĞ ? ƐƵďŐƌŽƵƉ ŽĨ ƉĞŽƉůĞ ǁŚŽ ŵĂǇ ŚĂǀĞ ƉĂůůŝĂƚŝǀĞ ŶĞĞĚƐ ƐŚŽƌƚůǇ ĨŽůůŽǁŝŶŐ ĚŝĂŐŶŽƐŝƐ ?
Given the high mortality, risk of acute catastrophic events and frequent hospital death, 
clarifying the level and timing of palliative care services engagement would help provide 
assurance as to whether palliative care needs are being met. Effective models of palliative 
care that provide timely support, potentially including access to Specialist Palliative Care 
teams at the time of treatment planning, are important to support both people with head 
and neck cancer and their family carers.  
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